- Home
- ACHC vs SPRY Comparison
ACHC vs SPRY Comparison
Compare ACHC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- SPRY
- Stock Information
- Founded
- ACHC 2005
- SPRY 2015
- Country
- ACHC United States
- SPRY United States
- Employees
- ACHC N/A
- SPRY N/A
- Industry
- ACHC Medical Specialities
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- ACHC Health Care
- SPRY Health Care
- Exchange
- ACHC Nasdaq
- SPRY Nasdaq
- Market Cap
- ACHC 1.7B
- SPRY 1.8B
- IPO Year
- ACHC N/A
- SPRY N/A
- Fundamental
- Price
- ACHC $19.24
- SPRY $17.50
- Analyst Decision
- ACHC Strong Buy
- SPRY Strong Buy
- Analyst Count
- ACHC 9
- SPRY 4
- Target Price
- ACHC $47.50
- SPRY $28.75
- AVG Volume (30 Days)
- ACHC 2.1M
- SPRY 1.1M
- Earning Date
- ACHC 08-05-2025
- SPRY 08-13-2025
- Dividend Yield
- ACHC N/A
- SPRY N/A
- EPS Growth
- ACHC N/A
- SPRY N/A
- EPS
- ACHC 1.52
- SPRY N/A
- Revenue
- ACHC $3,229,609,000.00
- SPRY $97,122,000.00
- Revenue This Year
- ACHC $7.80
- SPRY N/A
- Revenue Next Year
- ACHC $8.56
- SPRY $170.64
- P/E Ratio
- ACHC $12.64
- SPRY N/A
- Revenue Growth
- ACHC 5.64
- SPRY 971120.00
- 52 Week Low
- ACHC $17.13
- SPRY $9.52
- 52 Week High
- ACHC $82.41
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- ACHC 37.45
- SPRY 50.83
- Support Level
- ACHC $17.13
- SPRY $17.34
- Resistance Level
- ACHC $22.51
- SPRY $18.63
- Average True Range (ATR)
- ACHC 1.22
- SPRY 0.63
- MACD
- ACHC -0.40
- SPRY -0.12
- Stochastic Oscillator
- ACHC 35.17
- SPRY 27.56
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.